JB
Therapeutic Areas
Chrysalis BioTherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TP508 (Chrysalin™, rusalatide acetate) | Acute Respiratory Distress Syndrome (ARDS) from COVID-19 and non-COVID causes (infection, inflammation, traumatic injury) | Phase 1/2 |
Leadership Team at Chrysalis BioTherapeutics
DH
Darrell H. Carney, PhD
President, CEO and Board Chair
LS
Laurie Sower, PhD
Executive Vice President
GM
Gerald M Fuller, PhD
VP of Research
SP
Steven Pikulin, PhD
Director, Product Development /CMC
JT
James T. Ryaby, PhD
Member, Board of Directors
JS
Jeffery Sheldon, MBA
Member, Board of Directors
T(
Timothy (Tim) Schmidt, MBA
Member, Board of Directors